Pulsar18 Self-Expanding Stent System

Indicated for use in patients with atherosclerotic disease of the femoral and infrapopliteal arteries and for the treatment of insufficient results after Percutaneous Transluminal Angioplasty (PTA).*

Pulsar 18 product image

Product Highlights

People icon

140 μm thin struts

Thinner than the leading brands1

Coating icon

4F low profile

Improved acute outcomes vs. 6F2

Arrow icon

Clinically proven2,3

Long term safety and efficacy (24-month data), even in calcified lesions4,5


Proximal Shaft
Catheter type OTW
Recommended guide wire 0.018”
Stent material Nitinol
Strut thickness 140 μm
Strut width 85 μm
Stent coating proBIO™ (Amorphous Silicon Carbide)
Stent markers 6 gold markers each end
Sizes ø 4.0 - 7.0 mm; L:20 - 200 mm
Proximal shaft 3.6F, hydrophobic coating
Usable length 90 cm and 135 cm


Stent

ø (mm)
Catheter length 90 cm

Stent length (mm)
20 30 40 60 80 100 120 150 170 200
4F 4 377456 377457 377458 377459 377460 366808 366809 3366810 366811 3366812
5 377461 377462 377463 377464 377465 366813 366814 3366815 3366816 366817
6 377466 377467 377468 377469 377470 366818 366819 3366820 366821 366822
7 377471 377472 377473 377474 377475 366823 3366824 366825 366826 366827
Stent

ø (mm)
Catheter length 135 cm

Stent length (mm)
20 30 40 60 80 100 120 150 170 200
4F 4 377476 377477 377478 377479 377480 366828 366829 366830 366831 366832
5 377481 377482 377483 377484 377485 366833 366834 366835 366836 366837
6 377486 377487 377488 377489 377490 366838 366839 366840 366841 366842
7 377491 377492 377493 377494 377495 366843 366844 366845 366846 366847

IFU Link

Refer to this IFU link for a copy of the Instructions for Use and for a complete listing of the indications, contraindications, warnings and precautions.

References:

1. Data on file. 6.0 mm diameters. Leading competitors have been selected based on the PV Stent Revenue Market Shares EU, 2017 and PV Revenue Market Shares APAC 2015; (Source: Millennium Research Group Inc.); 2. Bosiers M. et al. 4-French - compatible endovascular material is safe & effective in the treatment of femoropopliteal occlusive disease: Results of the 4EVER Trial. ENDOVASC THER 2013; 20: 746-756; 3. Lichtenberg M. Superficial Femoral Artery TASC D registry: 12-month effectiveness analysis of the Pulsar-18 SE nitinol stent in patients with critical limb ischemia. J Cardiovasc Surg (Torino). 2013 ; 54(4):433-9; 4. Lichtenberg et al. Effectiveness of the Pulsar-18 self-expanding stent with optional drug-coated balloon angioplasty in the treatment of femoropopliteal lesions - the BIOFLEX PEACE All-Comers Registry.Vasa (2019), 1-9. doi_10.10240301-1526a0007853. 5. Bosiers M. 4EVER 24 month results: long-term results of 4F Pulsar stent in femoropopliteal lesions. Presented at: CIRSE 2013; Barcelona, Spain.

Teleflex, the Teleflex logo, proBIO and Pulsar are trademarks or registered trademarks of Teleflex Incorporated or its affiliates in the U.S and/or other countries. All other names are the trademarks or registered trademarks of their respective owners. Refer to this IFU link for a copy of the Instructions for Use and for a complete listing of the indications, contraindications, warnings and precautions. Information in this material is not a substitute for the product Instructions for Use. Not all products may be available in all countries.
© 2025 Teleflex Incorporated. All rights reserved.